# Blank Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/blank-bio

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.blank.bio
- Total disclosed funding: $7.2M
- Latest round: Seed (May 19, 2026)
- Investors on record: 6

## About

Based in the US, Blank Bio specializes in artificial intelligence solutions for precision oncology, utilizing RNA data to enhance clinical trial outcomes for pharmaceutical companies.Founded in 2025 and headquartered in San Francisco, US, Blank Bio focuses on RNA intelligence solutions. The company raised USD 7.2 million in Seed funding on May 19, 2026, with investments from Define Ventures, Leonis Capital, Nova Threshold, Ripple Ventures, SignalFire, and Y Combinator. This funding supports its aim to optimize clinical trials through innovative RNA modeling techniques.Blank Bio’s core offerings center around advanced RNA intelligence solutions designed to optimize clinical trial outcomes in precision oncology. The company specializes in two primary applications: disease trajectory modeling and patient selection. Through sophisticated RNA prognostic scores, Blank Bio predicts disease progression based on individual molecular profiles, enabling pharmaceutical teams to design more efficient trials that achieve statistical power with fewer patients. Additionally, the patient selection service helps identify biological differences among patients to pinpoint those most likely to respond to specific therapies, thereby enhancing treatment efficacy and informing combination strategies. Target customers include pharmaceutical companies and clinical development teams primarily in North America and Europe, where there is a growing demand for precise and actionable insights in drug development.Blank Bio's revenue model is structured around partnerships and B2B transactions with pharmaceutical companies, focusing on delivering tailored insights through its RNA intelligence services. The company establishes collaborations with clients, which involve subscriptions or contracts that allow access to its modeling capabilities and analytical tools. Client engagements typically revolve around the integration of Blank Bio's predictive models into the clients' clinical trial processes, thus facilitating improved patient selection and designing trials that maximize efficiency. Specific pricing plans are structured based on the scope of services provided, aligning with the client's needs and the complexity of the required analyses. This approach not only fosters long-term relationships but also positions Blank Bio as a critical partner in advancing precision oncology initiatives.In May 2026, Blank Bio secured USD 7.2 million in Seed funding to support RNA model development, expand partnerships, and generate sequencing datasets for oncology applications. The company plans to launch new RNA models aimed at enhancing clinical trial efficacy within the next 18 months. Additionally, Blank Bio is targeting expansion into European markets to meet increasing demand for precision oncology solutions, with initiatives aimed for completion by the end of 2027.

## Funding rounds

- Seed, May 19, 2026, $7.2M — Y Combinator, SignalFire, Ripple Ventures, Define Ventures, Leonis Capital, Nova Threshold

## Investors

- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- SignalFire (https://capitalatlas.ai/funds/signalfire) — Seed
- Ripple Ventures (https://capitalatlas.ai/funds/ripple-ventures) — Seed
- Define Ventures (https://capitalatlas.ai/funds/define-ventures) — Seed
- Leonis Capital (https://capitalatlas.ai/funds/leonis-capital) — Seed
- Nova Threshold — Seed